Email Updates

Search form

You are here

PrEP

Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

The World Health Organization (WHO) has updated its recommendation for pre-exposure prophylaxis (PrEP) to include event-driven PrEP taken before and after sex – also called on-demand PrEP or the 2+1+1 schedule – as an HIV prevention option for men who have sex with men.

July 24, 2019
aidsmap

First in-human data found that an implant for pre-exposure prophylaxis (PrEP) for HIV prevention was safe and long-acting, according to a small phase I trial presented here.

July 23, 2019
MedPage Today

It took universal health care, political will and a health campaign designed to terrify the public, but nearly four decades into the HIV crisis, Australian researchers say the country is on a path toward making transmissions of the virus vanishingly rare.

July 10, 2019
New York Times

The recommendation received an A grade, meaning it is well supported by scientific evidence. This is important because the Affordable Care Act (ACA) requires private insurers to cover preventive services recommended by the US Preventive Services Task Force with an “A” or “B” rating. The task force also released a recommendation for routine HIV screening for people ages 15 to 65 and for all pregnant women, also with an “A” grade.

June 11, 2019
POZ
Subscribe to RSS - PrEP